
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26754576</article-id><article-id pub-id-type="pmc">4709878</article-id><article-id pub-id-type="publisher-id">176</article-id><article-id pub-id-type="doi">10.1186/s12944-016-0176-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The rs5888 single nucleotide polymorphism in scavenger receptor class B type 1 (SCARB1) gene and the risk of premature coronary artery disease: a case-control study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goodarzynejad</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Boroumand</surname><given-names>Mohammadali</given-names></name><address><phone>(0098 21) 8802 9231</phone><email>maboroumand@yahoo.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Behmanesh</surname><given-names>Mehrdad</given-names></name><address><phone>(0098 21) 8288 4451</phone><email>behmanesh@modares.ac.ir</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Ziaee</surname><given-names>Shayan</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Jalali</surname><given-names>Arash</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Cardiac Research, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran </aff><aff id="Aff2"><label/>Department of Molecular Pathology, Tehran Heart Center, Tehran University of Medical Sciences, North Karegar Ave.and Jalal-Al-Ahmad cross, Tehran, Iran </aff><aff id="Aff3"><label/>Department of Genetics, School of Biological Sciences, Tarbiat Modares University, P.O. Box: 14115-154, Tehran, Iran </aff><aff id="Aff4"><label/>Department of Laboratory Medicine and Pathology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>15</volume><elocation-id>7</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Goodarzynejad et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Several single nucleotide polymorphisms (SNPs) in lipid transport genes have been shown to be associated with premature coronary artery disease (PCAD). The scavenger receptor BI (SCARB1) is a key component of the reverse cholesterol transport and lipid metabolism. We aimed to examine the relationship between the rs5888 SNP within SCARB1and the risk of angiographically determined PCAD.</p></sec><sec><title>Methods</title><p>We used an age cut-off of 55&#x000a0;years for women and 45&#x000a0;years for men to define PCAD. Five-hundred and five patients with newly diagnosed angiographically documented PCAD (&#x02265;50&#x000a0;% luminal stenosis of any coronary vessel) as case group compared with 546 controls (subjects with no luminal stenosis at coronary arteries). The severity of CAD was determined by vessel score as well as Gensini score. A real-time polymerase chain reaction (PCR) and High Resolution Melting (HRM) analysis was used to distinguish between genotypes.</p></sec><sec><title>Results</title><p>T allele as compared to C allele was associated with increased odds of PCAD in total population (adjusted OR&#x02009;=&#x02009;1.3, 95&#x000a0;% CI&#x02009;=&#x02009;1.0 to 1.5; <italic>p</italic>&#x02009;=&#x02009;0.020), and in women (adjusted OR&#x02009;=&#x02009;1.3, 95&#x000a0;% CI&#x02009;=&#x02009;1.0 to 1.8; <italic>p</italic>&#x02009;=&#x02009;0.037), but not in men (adjusted OR&#x02009;=&#x02009;1.2, 95&#x000a0;% CI&#x02009;=&#x02009;0.9 to 1.5; <italic>p</italic>&#x02009;=&#x02009;0.311). There was also no significant association between the examined polymorphism and the severity of CAD in whole or in men or women subgroups.</p></sec><sec><title>Conclusions</title><p>Our findings suggest that the SNP (rs5888) within SCARB1 is independently associated with PCAD in a sex-dependent manner.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Coronary artery disease</kwd><kwd>Premature atherosclerosis</kwd><kwd>Coronary angiography</kwd><kwd>Scavenger receptor class B type I</kwd><kwd>rs5888 polymorphism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>The occurrence of coronary artery disease (CAD) in younger subjects, although infrequent, causes devastating effect on the more active lifestyle of this group of patients and may result in premature death [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients with premature CAD (PCAD), defined as the presence of coronary artery atherosclerotic lesion in men &#x02264;45&#x000a0;year and women &#x02264;55&#x000a0;years, have different risk factor profiles, clinical presentations, and prognoses than older patients [<xref ref-type="bibr" rid="CR2">2</xref>]. Even though the identification of risk factors for PCAD is of essential importance for the understanding of its origins and for establishing preventive strategies, the mechanisms and predictors of PCAD are still not completely understood [<xref ref-type="bibr" rid="CR3">3</xref>]. Risk factors for CAD are both environmental and genetic. In patients with PCAD, the role of genetic risk factors is expected to be more important than that of environmental factors [<xref ref-type="bibr" rid="CR4">4</xref>]. Over the past recent years, several single nucleotide polymorphisms (SNPs) in lipid transport genes have been shown to be associated with PCAD [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Scavenger receptor class B type1 (SCARB1, also called SR-BI) is a multiligand cell surface receptor expresses both in macrophages and in the liver, indicating a major role for in the clearance of excess cholesterol from the body [<xref ref-type="bibr" rid="CR10">10</xref>]. This membrane protein facilitates the uptake of cholesteryl esters from high-density lipoprotein cholesterol (HDL-C) and drives cholesterol from tissues to the liver in the various stages of reverse cholesterol transport pathway. This makes SCARB1 gene as an attractive candidate gene for CAD. The SCARB1 gene is located on 12q24.31 encompassing 13 exons and spans approximately 75&#x000a0;kb. Various SCARB1 polymorphisms in humans have been shown to be associated with altered serum lipid profile but their influence on CAD development or severity is still unclear [<xref ref-type="bibr" rid="CR11">11</xref>]. One exonic SNP (rs5888) within SCARB1, has been linked to lower SR-BI protein expression and function [<xref ref-type="bibr" rid="CR12">12</xref>]. This SNP is a &#x0201c;C&#x0201d; to &#x0201c;T&#x0201d; substitution at cDNA position 1050 base position on exon 8, and a coding-synonymous polymorphism (A350A) which was initially found by Acton et al. [<xref ref-type="bibr" rid="CR13">13</xref>]. Several studies on rs5888 polymorphism and the risk of CAD have been previously published with contradictory results [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. There is even controversy about which allele confers increased risk. Wu et al. [<xref ref-type="bibr" rid="CR14">14</xref>] found that the individuals with TT genotype were associated with increased CAD risk, whereas others reported that the T allele or the T allele carrier was associated with decreased risk of CAD [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Moreover, they have investigated this association amongst general CAD populations and there is no study, that we are aware of, studying this association in PCAD patients. Thus, the aim of the present study was to examine the relation of rs5888 SNP with the presence and severity of angiographically determined PCAD in an Iranian coronary population.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study participants and coronary angiograms</title><p>A prior study has used an age cut-off of 55&#x000a0;years for women and 45&#x000a0;years for men to define &#x0201c;young&#x0201d; patients with CAD [<xref ref-type="bibr" rid="CR20">2</xref>]. To define PCAD, the same age definition was used in this study. This age- and sex-matched case&#x02013;control study was conducted on 560 patients with newly diagnosed angiographically documented PCAD and an equal number of controls with normal coronary arteries. Cases were selected consecutively from those who, between August 2009 and May 2011, underwent coronary angiography at the catheterization laboratory of our center because of symptoms related to CAD or the results of non-invasive tests. Unrelated matched controls were selected from a pool of 1547 young patients (419 men and 1128 women) who, between June 2004 and July 2011, consecutively admitted for elective coronary angiography at our hospital. Cases and controls were matched for age within two years. Exclusion criteria included previous history of acute myocardial infarction (MI), stent implantation, cardiopulmonary resuscitation (CPR), and coronary artery bypass graft surgery. Also, patients on lipid-lowering drugs and those with minimal CAD (coronary lesions with less than 50&#x000a0;% luminal stenosis) were excluded. The study protocol was approved by the local ethical committee. Written informed consent was obtained from all patients in agreement with the Declaration of Helsinki for research involving human subjects explicitly provided permission for DNA analyses and gathering the relevant clinical data.</p><p>Coronary angiographies were performed by the percutaneous femoral approach using standard techniques. The presence and severity of CAD was determined by clinical vessel score. All cases showed the evidence of atherosclerosis i.e., &#x02265; 50&#x000a0;% luminal stenosis in at least one coronary artery or major branch segment in their epicardial coronary tree. Controls had no luminal stenosis at coronary angiograph. The severity of CAD was also determined by a semi-quantitative scoring system (Gensini score) which has been previously described [<xref ref-type="bibr" rid="CR19">19</xref>]. Two cardiologists, blind to the study results, interpreted all angiograms. Definitions for analyzed risk factors of CAD including, body mass index (BMI), dyslipidemia, hypertension, cigarette smoking, opium addiction, and diabetes have been reported elsewhere [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Sample collection and DNA extraction</title><p>From June 2004 to July 2011, for the purpose of creating a &#x0201c;DNA-bank of patients with PCAD and controls&#x0201d;, all young patients (age &#x02264;45&#x000a0;years for men, and age &#x02264;55&#x000a0;years for women at the disease onset) admitted for elective coronary angiography at our center were asked to provide a sample of whole blood for DNA extraction Peripheral venous blood samples were collected from an antecubital vein after 12&#x000a0;h overnight fasting of participants. Upon arrival at the laboratory, each participant provided about 15-mL venous blood sample. 5&#x000a0;mL blood was collected in plain tubes and used for biochemical assays immediately; the rest of the sample (10&#x000a0;ml) placed in ethylenediamine tetraacetic acid (EDTA)-containing tubes and stored deep-frozen until later use. Genomic DNA was extracted from leukocytes using the buffy coat of the stored EDTA whole blood samples. DNA extraction carried out using the standard &#x02018;salting out&#x02019; method. DNA quantity was evaluated by calculating absorbance at &#x003bb;&#x02009;=&#x02009;260&#x000a0;nm, and the quality was assessed by a ratio of &#x003bb;&#x02009;=&#x02009;260/280&#x000a0;nm being close to 1.8. The purified DNA was stored in Tris-EDTA buffer (pH&#x000a0;8.0) at &#x02013;70&#x000a0;&#x000b0;C until further analysis.</p></sec><sec id="Sec5"><title>PCR amplification and genotype analysis</title><p>Real-time polymerase chain reaction (PCR) and High-Resolution Melting (HRM) analysis was applied for the genotype analysis using Corbett Rotor-Gene 6000 real-time rotary analyzer (Corbett Life Science Pty. Ltd., Mortlake, NSW, Australia). One set of primers based on common HRM specifications was designed using Beacon Designer software version 7.0 (Premier Biosoft International, Palo Alto, CA, USA) and synthesized by Bioneer Inc. (Daejeon, Korea). The forward primer was 5&#x02032;- CTTGTTTCTCTCCCATCCTCA -3&#x02032; and the reverse was 5&#x02032;- GAGTGTGCCTCCTGGTTAG -3&#x02032;. The final reaction mixture contained Type-it HRM Master Mix (QIAGEN NV, Venlo, Netherlands) with intercalating DNA-binding Evagreen dye (Biotium, Inc. Hayward, CA, USA), DNA polymerase (5U/ml), primer mix (0.4&#x000a0;&#x003bc;M of each primer), genomic DNA (50&#x000a0;ng), and RNase Free Water (QIAGEN NV) in a total volume of 20&#x000a0;&#x003bc;l. The PCR cycling conditions consisted of an initial denaturation at 95&#x000a0;&#x000b0;C for 15&#x000a0;min, followed by 37&#x000a0;cycles of denaturation (96&#x000a0;&#x000b0;C for 20&#x000a0;s), primer annealing (62&#x000a0;&#x000b0;C for 20&#x000a0;s), and extension (72&#x000a0;&#x000b0;C for 15&#x000a0;s). One positive control for each genotype (CC, CT, and TT) and one appropriate negative control were included in each run. The positive controls were verified by using the PCR with restriction fragment length polymorphism (RFLP) technique as described previously with minor modification [<xref ref-type="bibr" rid="CR22">22</xref>]. The genotypes were separated by electrophoresis on 2&#x000a0;% agarose gel stained with ethidium bromide (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) and also confirmed by direct DNA sequence analysis.<fig id="Fig1"><label>Fig. 1</label><caption><p>Agarose gel electrophoresis for the rs5888 polymorphism of scavenger receptor class B type 1 (SCARB1) gene. The 218-bp PCR product of SCARB1 rs5888 (C&#x02009;&#x0003e;&#x02009;T) was digested by Hin1I (BsaHI) restriction enzyme. The C allele codes for the presence of the Hin1I site and the T allele codes its absence. The wild-type CC variant produced two fragments with 187&#x000a0;bp and 31&#x000a0;bp while heterozygote CT produced 3 fragments of 218&#x000a0;bp, 187&#x000a0;bp, and 31&#x000a0;bp. The mutated homozygous variant TT produced one fragment of 218&#x000a0;bp. The 31&#x000a0;bp fragment was not visible in the gel due to its fast migration speed. M, 50&#x000a0;bp marker ladder; Lanes 6 and 10, CC genotype; Lanes 2, 5, 7, 8, 9, and 12, CT genotype; Lanes 1, 3, 4, and 11, TT genotype</p></caption><graphic xlink:href="12944_2016_176_Fig1_HTML" id="MO1"/></fig></p><p>Following the PCR amplification steps, melt curves for the products were generated by heating in 0.1&#x000a0;&#x000b0;C increments at a rate of 2&#x000a0;s per each step over the temperature range from 65 to 95&#x000a0;&#x000b0;C. The HRM data were analyzed using the Rotor-Gene Q software package supplied with the instrument. Sequence variations were distinguished from wild-type samples by the different shapes of normalized and temperature-shifted melting curves. In samples which failed to give an interpretable HRM pattern (10&#x000a0;%), the PCR-RFLP method was used for genotyping and reconfirmed by direct sequencing in 15 samples.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Continuous variables are reported as &#x0201c;mean&#x02009;&#x000b1;&#x02009;standard deviation&#x0201d; and categorical variables as &#x0201c;numbers and percentage&#x0201d;. Variables were tested for normality by visually inspection of box-plots and by using Kolmogorov&#x02013;Smirnov normality test. Gensini score, which was skewed, presented as median and inter-quartile range (25<sup>th</sup> to 75th percentiles). The case and control groups were compared using the independent two-sample Student <italic>t</italic>-test (or Mann-Whitney <italic>U</italic>-test if required) for the continuous variables and the chi-square test (or the Fisher exact test, as appropriate) for the categorical variables. Due to the highly skewed distribution of Gensini scores, to compare Gensini score among rs5888 genotypes, the Kruskal-Wallis analysis was chosen and subjects with normal coronary arteries (Gensini score&#x02009;=&#x02009;0, <italic>n</italic>&#x02009;=&#x02009;546) were excluded to ensure any observed effect on graded severity was not being driven by those without any CAD in whom risk allele frequency is expected to be significantly lower.</p><p>Logistic regression model was constructed to test the independent relationship between the rs5888 variants and the presence of CAD with the SNP coded as 0, 1, or 2 based on the number of risk (T) alleles. Analyses were repeated after adjusting for diabetes mellitus, cigarette smoking, opium addiction, hypertension, and family history of CAD as well as serum HDL-C, triglyceride, and LDL-C in an established multivariable model. Odds ratio (OR) and 95&#x000a0;% confidence intervals (CI) were calculated in all patients and in males and females separately. Moreover, a linear multiple regression analysis with the presence of CAD severity (Gensini score as a continuous variable) as the dependent variable, was performed. The following were tested as potential risk factors: diabetes mellitus, cigarette smoking, opium addiction, hypertension, and family history of CAD as well as BMI and serum levels of HDL-C, triglyceride, and LDL-C. Non-normal variables, such as Gensini scores, were natural log-transformed before entering the model. Additionally, a multiple ordinal logistic regression model, with number of diseased vessels as the dependent variable, was established with adjusting for aforementioned potential risk factors. A generalized linear model (GLM) was used to analyze the association between the genotypes and lipid profile adjusted for age, sex, BMI, and cigarette smoking. A <italic>p</italic> value&#x02009;&#x02264;&#x02009;0.05 was considered statistically significant. All Statistical analyses were done by PASW Statistics for Windows, Version 18.0. (Chicago: SPSS Inc.).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>Sixty-nine patients (55 cases and 14 controls) were excluded due to missing data or genotyping failure, resulting in 1051 patients entered in the statistical analyses including 505 cases, and 546 controls. The mean age of the study participants was 46&#x02009;&#x000b1;&#x02009;6&#x000a0;years and 45.4&#x000a0;% were men. Baseline characteristics of the study sample stratified by gender and CAD status are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>, respectively. The overall prevalence of cardiovascular risk factors including, hypertension, diabetes mellitus, cigarette smoking, dyslipidemia, and family history of CAD were high. The women had a greater prevalence of hypertension, diabetes mellitus, and dyslipidemia as compared to men but cigarette smoking and opium addiction were much more frequent in men than in women. There was no significant difference in the prevalence of family history of CAD between men and women (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). As seen in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, the prevalence of diabetes, family history of CAD, hyperlipidemia, and cigarette smoking as well as hypertension and opium addiction were significantly higher in CAD group whereas there was no statistically significant difference in age, sex, and BMI between two groups.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of the study population stratified by sex</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All (<italic>n</italic>&#x02009;=&#x02009;1051)</th><th>Men (<italic>n</italic>&#x02009;=&#x02009;477)</th><th>Women (<italic>n</italic>&#x02009;=&#x02009;574)</th><th>
<italic>P</italic>-value<sup>*</sup>
</th></tr></thead><tbody><tr><td>Age (years)</td><td>45.6&#x02009;&#x000b1;&#x02009;6.0</td><td>41.0&#x02009;&#x000b1;&#x02009;3.5</td><td>49.4&#x02009;&#x000b1;&#x02009;4.9</td><td>&#x0003c;0.001</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>29.7&#x02009;&#x000b1;&#x02009;5.7</td><td>28.1&#x02009;&#x000b1;&#x02009;4.4</td><td>31.1&#x02009;&#x000b1;&#x02009;5.3</td><td>&#x0003c;0.001</td></tr><tr><td>Cigarette smoking</td><td/><td/><td/><td>&#x0003c;0.001</td></tr><tr><td>&#x02003;Current smoker</td><td>213 (20.3)</td><td>188 (39.4)</td><td>25 (4.4)</td><td/></tr><tr><td>&#x02003;Ex-smoker</td><td>97 (9.2)</td><td>82 (17.2)</td><td>15 (2.6)</td><td/></tr><tr><td>&#x02003;Non-smoker</td><td>741 (70.5)</td><td>207 (43.4)</td><td>534 (93.0)</td><td/></tr><tr><td>Opium addiction</td><td>99 (9.4)</td><td>91 (19.1)</td><td>8 (1.4)</td><td>&#x0003c;0.001</td></tr><tr><td>Hypertension</td><td>456 (44.3)</td><td>126 (26.4)</td><td>339 (59.1)</td><td>&#x0003c;0.001</td></tr><tr><td>Diabetes</td><td>240 (22.8)</td><td>53 (11.1)</td><td>187 (32.6)</td><td>&#x0003c;0.001</td></tr><tr><td>Dyslipidemia</td><td>673 (64.0)</td><td>290 (60.8)</td><td>383 (66.7)</td><td>0.046</td></tr><tr><td>Family history of CAD</td><td>357 (34.0)</td><td>157 (32.9)</td><td>200 (34.8)</td><td>0.511</td></tr><tr><td>Fasting blood glucose (mg/dl)</td><td>116.7&#x02009;&#x000b1;&#x02009;50.1</td><td>106.8&#x02009;&#x000b1;&#x02009;41.1</td><td>124.8&#x02009;&#x000b1;&#x02009;52.2</td><td>&#x0003c;0.001</td></tr><tr><td>Triglyceride (mg/dl)</td><td>182.8&#x02009;&#x000b1;&#x02009;116.4</td><td>193.3&#x02009;&#x000b1;&#x02009;123.1</td><td>174.1&#x02009;&#x000b1;&#x02009;109.9</td><td>0.008</td></tr><tr><td>HDL-cholesterol (mg/dl)</td><td>42.2&#x02009;&#x000b1;&#x02009;11.7</td><td>38.5&#x02009;&#x000b1;&#x02009;10.5</td><td>45.2&#x02009;&#x000b1;&#x02009;11.8</td><td>&#x0003c;0.001</td></tr><tr><td>LDL-cholesterol (mg/dl)</td><td>117.0&#x02009;&#x000b1;&#x02009;40.3</td><td>113.4&#x02009;&#x000b1;&#x02009;37.1</td><td>119.9&#x02009;&#x000b1;&#x02009;42.5</td><td>0.011</td></tr><tr><td>Total cholesterol (mg/dl)</td><td>186.8&#x02009;&#x000b1;&#x02009;48.6</td><td>182.2&#x02009;&#x000b1;&#x02009;47.7</td><td>190.6&#x02009;&#x000b1;&#x02009;49.5</td><td>0.005</td></tr><tr><td>Creatinine (mg/dl)</td><td>0.9&#x02009;&#x000b1;&#x02009;0.6</td><td>1.0&#x02009;&#x000b1;&#x02009;0.8</td><td>0.8&#x02009;&#x000b1;&#x02009;0.4</td><td>&#x0003c;0.001</td></tr><tr><td>LVEF (%)</td><td>53.8&#x02009;&#x000b1;&#x02009;9.0</td><td>52.7&#x02009;&#x000b1;&#x02009;9.7</td><td>54.7&#x02009;&#x000b1;&#x02009;8.3</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD or n (%)</p><p>
<italic>CAD</italic> Coronary artery disease, <italic>LVEF</italic> left ventricular ejection fraction</p><p>
<sup>*</sup>
<italic>P</italic>-values for men vs. women</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline characteristics in the study population based on coronary artery disease presence</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>non-CAD (<italic>n</italic>&#x02009;=&#x02009;546)</th><th>CAD (<italic>n</italic>&#x02009;=&#x02009;505)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Age (years)</td><td>45.6&#x02009;&#x000b1;&#x02009;6.1</td><td>45.6&#x02009;&#x000b1;&#x02009;5.9</td><td>0.922</td></tr><tr><td>Body mass index (Kg/m<sup>2</sup>)</td><td>29.7&#x02009;&#x000b1;&#x02009;4.9</td><td>29.7&#x02009;&#x000b1;&#x02009;5.4</td><td>0.996</td></tr><tr><td>Male sex</td><td>243 (44.5)</td><td>234 (46.3)</td><td>0.551</td></tr><tr><td>Diabetes mellitus</td><td>74 (13.6)</td><td>166 (32.9)</td><td>&#x0003c;0.001</td></tr><tr><td>Hypertension</td><td>192 (35.2)</td><td>273 (54.1)</td><td>&#x0003c;0.001</td></tr><tr><td>Smoking status</td><td/><td/><td>0.001</td></tr><tr><td>&#x02003;Current smoker</td><td>87 (15.9)</td><td>126 (25.0)</td><td/></tr><tr><td>&#x02003;Ex-smoker</td><td>48 (8.8)</td><td>49 (9.7)</td><td/></tr><tr><td>&#x02003;Non-smoker</td><td>411 (75.3)</td><td>330 (65.3)</td><td/></tr><tr><td>Family history of CAD</td><td>148 (27.1)</td><td>209 (41.4)</td><td>&#x0003c;0.001</td></tr><tr><td>Dyslipidemia</td><td>315 (57.7)</td><td>342 (72.6)</td><td>&#x0003c;0.001</td></tr><tr><td>Triglyceride (mg/dl)</td><td>173.4&#x02009;&#x000b1;&#x02009;114.3</td><td>193.0&#x02009;&#x000b1;&#x02009;118.0</td><td>0.007</td></tr><tr><td>HDL-cholesterol (mg/dl)</td><td>43.9&#x02009;&#x000b1;&#x02009;11.5</td><td>40.2&#x02009;&#x000b1;&#x02009;11.7</td><td>&#x0003c;0.001</td></tr><tr><td>LDL-cholesterol (mg/dl)</td><td>116.4&#x02009;&#x000b1;&#x02009;36.3</td><td>117.6&#x02009;&#x000b1;&#x02009;44.2</td><td>0.945</td></tr><tr><td>Total cholesterol (mg/dl)</td><td>186.9&#x02009;&#x000b1;&#x02009;42.8</td><td>186.8&#x02009;&#x000b1;&#x02009;54.3</td><td>0.996</td></tr><tr><td>Fasting blood glucose (mg/dl)</td><td>106.1&#x02009;&#x000b1;&#x02009;36.7</td><td>128.3&#x02009;&#x000b1;&#x02009;60.2</td><td>&#x0003c;0.001</td></tr><tr><td>Creatinine (mg/dl)</td><td>0.9&#x02009;&#x000b1;&#x02009;0.6</td><td>0.9&#x02009;&#x000b1;&#x02009;0.6</td><td>0.981</td></tr><tr><td>LVEF (%)</td><td>55.7&#x02009;&#x000b1;&#x02009;8.0</td><td>51.7&#x02009;&#x000b1;&#x02009;9.6</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD or <italic>n</italic> (%)</p><p>
<italic>CAD</italic> Coronary artery disease, <italic>LVEF</italic> left ventricular ejection fraction</p></table-wrap-foot></table-wrap></p><p>Allele and genotype frequencies for the SCARB1 (rs5888) polymorphism in the case and control groups, separated by sex, are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There was no statistically significant difference in the distribution of rs5888 genotypes between two groups and in men and women subgroups after stratification by sex. Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> shows that no associations were detected between SCARB1 rs5888 (C&#x02009;&#x0003e;&#x02009;T) genotypes and lipid profile including total cholesterol, HDL-C, LDL-C, and triglyceride levels. Even after analyzing data separately for men or women, the rs5888 SNP in SCARB1 gene was not associated with lipid profile in the subgroup of men or women (data not shown).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Genotype and allele frequencies of rs5888 polymorphism in the SCARB1 gene according to CAD status in whole study group and in subgroups separated by gender</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">non- CAD patients</th><th colspan="3">CAD patients</th><th colspan="3">
<italic>P</italic>-value<sup>*</sup>
</th></tr><tr><th/><th>All (<italic>n</italic>&#x02009;=&#x02009;546)</th><th>Male (<italic>n</italic>&#x02009;=&#x02009;243)</th><th>Female (<italic>n</italic>&#x02009;=&#x02009;303)</th><th>All (<italic>n</italic>&#x02009;=&#x02009;505)</th><th>Male (<italic>n</italic>&#x02009;=&#x02009;234)</th><th>Female (<italic>n</italic>&#x02009;=&#x02009;271)</th><th>All</th><th>Male</th><th>Female</th></tr></thead><tbody><tr><td>rs5888 (C&#x02009;&#x0003e;&#x02009;T)</td><td/><td/><td/><td/><td/><td/><td>0.163</td><td>0.781</td><td>0.143</td></tr><tr><td>&#x02003;CC</td><td>195 (35.7)</td><td>88 (36.2)</td><td>107 (35.3)</td><td>162 (32.1)</td><td>81 (34.6)</td><td>81 (29.9)</td><td/><td/><td/></tr><tr><td>&#x02003;CT</td><td>281 (51.5)</td><td>121 (49.8)</td><td>160 (52.8)</td><td>259 (51.3)</td><td>115 (49.1)</td><td>144 (53.1)</td><td/><td/><td/></tr><tr><td>&#x02003;TT</td><td>70 (12.8)</td><td>34 (14.0)</td><td>36 (11.9)</td><td>84 (16.6)</td><td>38 (16.2)</td><td>46 (17.0)</td><td/><td/><td/></tr><tr><td>&#x02003;CT&#x02009;+&#x02009;TT</td><td>351 (64.3)</td><td>155 (63.8)</td><td>196 (64.7)</td><td>343 (67.9)</td><td>153 (65.4)</td><td>190 (70.9)</td><td>0.214</td><td>0.715</td><td>0.167</td></tr><tr><td>Alleles</td><td/><td/><td/><td/><td/><td/><td>0.082</td><td>0.544</td><td>0.070</td></tr><tr><td>&#x02003;C</td><td>671 (61.4)</td><td>297 (61.1)</td><td>374 (61.7)</td><td>583 (57.7)</td><td>277 (59.2)</td><td>306 (56.5)</td><td/><td/><td/></tr><tr><td>&#x02003;T</td><td>421 (38.6)</td><td>189 (38.9)</td><td>232 (38.3)</td><td>427 (42.3)</td><td>191 (40.8)</td><td>236 (43.5)</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>
<sup>*</sup>
<italic>p</italic>-values for non-CAD vs. CAD</p><p>Data are presented as n (%)</p><p>CAD, Coronary artery disease; SCARB1, scavenger receptor class B type 1</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Lipid profile in total population, and in case and control groups according to rs5888 (C&#x02009;&#x0003e;&#x02009;T) genotypes in SCARB1 gene</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>CC</th><th>CT</th><th>TT</th><th>
<italic>P</italic> value*</th></tr></thead><tbody><tr><td>All participants</td><td>(<italic>n</italic>&#x02009;=&#x02009;357)</td><td>(<italic>n</italic>&#x02009;=&#x02009;540)</td><td>(<italic>n</italic>&#x02009;=&#x02009;154)</td><td>&#x02013;</td></tr><tr><td>&#x02003;Triglyceride (mg/dl)</td><td>183.6&#x02009;&#x000b1;&#x02009;108.7</td><td>179.6&#x02009;&#x000b1;&#x02009;113.7</td><td>192.5&#x02009;&#x000b1;&#x02009;140.5</td><td>0.572</td></tr><tr><td>&#x02003;HDL cholesterol (mg/dl)</td><td>41.8&#x02009;&#x000b1;&#x02009;11.6</td><td>42.6&#x02009;&#x000b1;&#x02009;12.1</td><td>41.4&#x02009;&#x000b1;&#x02009;10.4</td><td>0.569</td></tr><tr><td>&#x02003;LDL cholesterol (mg/dl)</td><td>119.5&#x02009;&#x000b1;&#x02009;40.2</td><td>115.9&#x02009;&#x000b1;&#x02009;40.3</td><td>114.9&#x02009;&#x000b1;&#x02009;40.4</td><td>0.351</td></tr><tr><td>&#x02003;Total cholesterol (mg/dl)</td><td>188.5&#x02009;&#x000b1;&#x02009;51.1</td><td>186.2&#x02009;&#x000b1;&#x02009;47.3</td><td>185.1&#x02009;&#x000b1;&#x02009;47.2</td><td>0.691</td></tr><tr><td>Non-CAD group</td><td>(<italic>n</italic>&#x02009;=&#x02009;195)</td><td>(<italic>n</italic>&#x02009;=&#x02009;281)</td><td>(<italic>n</italic>&#x02009;=&#x02009;70)</td><td>&#x02013;</td></tr><tr><td>&#x02003;Triglyceride (mg/dl)</td><td>175.7&#x02009;&#x000b1;&#x02009;113.2</td><td>166.0&#x02009;&#x000b1;&#x02009;99.0</td><td>196.4&#x02009;&#x000b1;&#x02009;162.6</td><td>0.065</td></tr><tr><td>&#x02003;HDL cholesterol (mg/dl)</td><td>43.5&#x02009;&#x000b1;&#x02009;12.6</td><td>44.3&#x02009;&#x000b1;&#x02009;11.0</td><td>43.8&#x02009;&#x000b1;&#x02009;9.5</td><td>0.853</td></tr><tr><td>&#x02003;LDL cholesterol (mg/dl)</td><td>120.6&#x02009;&#x000b1;&#x02009;36.2</td><td>113.0&#x02009;&#x000b1;&#x02009;34.6</td><td>118.2&#x02009;&#x000b1;&#x02009;41.6</td><td>0.054</td></tr><tr><td>&#x02003;Total cholesterol (mg/dl)</td><td>189.4&#x02009;&#x000b1;&#x02009;44.0</td><td>183.8&#x02009;&#x000b1;&#x02009;40.7</td><td>191.5&#x02009;&#x000b1;&#x02009;46.6</td><td>0.108</td></tr><tr><td>CAD group</td><td>(<italic>n</italic>&#x02009;=&#x02009;162)</td><td>(<italic>n</italic>&#x02009;=&#x02009;259)</td><td>(<italic>n</italic>&#x02009;=&#x02009;84)</td><td>&#x02013;</td></tr><tr><td>&#x02003;Triglyceride (mg/dl)</td><td>193.3&#x02009;&#x000b1;&#x02009;102.5</td><td>194.2&#x02009;&#x000b1;&#x02009;126.4</td><td>189.1&#x02009;&#x000b1;&#x02009;119.4</td><td>0.887</td></tr><tr><td>&#x02003;HDL cholesterol (mg/dl)</td><td>39.7&#x02009;&#x000b1;&#x02009;10.0</td><td>40.8&#x02009;&#x000b1;&#x02009;12. 9</td><td>39.3&#x02009;&#x000b1;&#x02009;10.7</td><td>0.499</td></tr><tr><td>&#x02003;LDL cholesterol (mg/dl)</td><td>118.2&#x02009;&#x000b1;&#x02009;44.5</td><td>119.0&#x02009;&#x000b1;&#x02009;45.4</td><td>112.0&#x02009;&#x000b1;&#x02009;39.4</td><td>0.470</td></tr><tr><td>&#x02003;Total cholesterol (mg/dl)</td><td>189.4&#x02009;&#x000b1;&#x02009;58.9</td><td>188.8&#x02009;&#x000b1;&#x02009;53.4</td><td>179.6&#x02009;&#x000b1;&#x02009;47.5</td><td>0.350</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for age, sex, cigarette smoking, and body mass index (BMI)</p><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD</p><p>CAD, Coronary artery disease; SCARB1, scavenger receptor class B type 1</p></table-wrap-foot></table-wrap></p><p>After applying a multiple logistic regression model with adjusting for diabetes, hypertension, cigarette smoking, opium addiction, BMI, and family history of CAD as well as triglyceride, HDL-C, and LDL-C, rs5888 polymorphism was found to be associated with the presence of PCAD in total population and in women but not in men (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). T allele as compared to C allele was associated with increased odds of PCAD in total population (adjusted OR&#x02009;=&#x02009;1.3, 95&#x000a0;% CI&#x02009;=&#x02009;1.0 to 1.5; <italic>p</italic>&#x02009;=&#x02009;0.020), and in women (adjusted OR&#x02009;=&#x02009;1.3, 95&#x000a0;% CI&#x02009;=&#x02009;1.0 to 1.8; <italic>p</italic>&#x02009;=&#x02009;0.037), but not in men (adjusted OR&#x02009;=&#x02009;1.2, 95&#x000a0;% CI&#x02009;=&#x02009;0.9 to 1.5; <italic>p</italic>&#x02009;=&#x02009;0.311). Among total population, those with TT genotype had 1.7-fold increased adjusted odds of PCAD compared to those with CC genotype (<italic>p</italic>&#x02009;=&#x02009;0.013). When data were analyzed separately for men or women, SCARB1 (rs5888) TT genotype as compared to CC genotype was associated with increased odds of PCAD in women (adjusted OR&#x02009;=&#x02009;2.1, 95&#x000a0;% CI&#x02009;=&#x02009;1.2 to 4.0; <italic>p</italic>&#x02009;=&#x02009;0.014), but not in men (adjusted OR&#x02009;=&#x02009;1.3, 95&#x000a0;% CI&#x02009;=&#x02009;0.7 to 2.5; <italic>p</italic>&#x02009;=&#x02009;0.336).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Unadjusted and adjusted odds ratios for the effect of rs5888 genotypes on premature coronary artery disease in whole and in men and women separately</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Unadjusted</th><th colspan="2">Adjusted*</th></tr><tr><th>rs5888 (C&#x02009;&#x0003e;&#x02009;T)</th><th>Odds ratio (95&#x000a0;% CI)</th><th>
<italic>p</italic>-value</th><th>Odds ratio (95&#x000a0;% CI)</th><th>
<italic>p</italic>-value</th></tr></thead><tbody><tr><td>All participants</td><td/><td>0.164</td><td/><td>0.046</td></tr><tr><td>&#x02003;CC</td><td>1.0 (Ref.)</td><td>-</td><td>1.0 (Ref.)</td><td>&#x02013;</td></tr><tr><td>&#x02003;CT</td><td>1.1 (0.9 to 1.5)</td><td>0.448</td><td>1.2 (0.9 to 1.6)</td><td>0.204</td></tr><tr><td>&#x02003;TT</td><td>1.4 (1.0 to 2.1)</td><td>0.058</td><td>1.7 (1.1 to 2.6)</td><td>0.013</td></tr><tr><td>&#x02003;CT&#x02009;+&#x02009;TT</td><td>1.2 (0.9 to 1.5)</td><td>0.214</td><td>1.3 (1.0 to 1.7)</td><td>0.077</td></tr><tr><td>&#x02003;Allele T vs. C</td><td>1.2 (1.0 to 1.4)</td><td>0.082</td><td>1.3 (1.0 to 1.5)</td><td>0.020</td></tr><tr><td>Male sex</td><td/><td>0.781</td><td/><td>0.583</td></tr><tr><td>&#x02003;CC</td><td>1.0 (Ref.)</td><td>&#x02013;</td><td>1.0 (Ref.)</td><td>&#x02013;</td></tr><tr><td>&#x02003;CT</td><td>1.0 (0.7 to 1.5)</td><td>0.874</td><td>1.2 (0.8 to 1.8)</td><td>0.448</td></tr><tr><td>&#x02003;TT</td><td>1.2 (0.7 to 2.1)</td><td>0.491</td><td>1.3 (0.7 to 2.5)</td><td>0.336</td></tr><tr><td>&#x02003;CT&#x02009;+&#x02009;TT</td><td>1.1 (0.7 to 1.6)</td><td>0.715</td><td>1.2 (0.8 to 1.9)</td><td>0.348</td></tr><tr><td>&#x02003;Allele T vs. C</td><td>1.1 (0.8 to 1.4)</td><td>0.544</td><td>1.2 (0.9 to 1.5)</td><td>0.311</td></tr><tr><td>Female sex</td><td/><td>0.146</td><td/><td>0.044</td></tr><tr><td>&#x02003;CC</td><td>1.0 (Ref.)</td><td>&#x02013;</td><td>1.0 (Ref.)</td><td>&#x02013;</td></tr><tr><td>&#x02003;CT</td><td>1.2 (0.8 to 1.7)</td><td>0.354</td><td>1.1 (0.7 to 1.8)</td><td>0.551</td></tr><tr><td>&#x02003;TT</td><td>1.7 (1.0 to 2.9)</td><td>0.050</td><td>2.1 (1.2 to 4.0)</td><td>0.014</td></tr><tr><td>&#x02003;CT&#x02009;+&#x02009;TT</td><td>1.3 (0.9 to 1.8)</td><td>0.167</td><td>1.3 (0.9 to 2.0)</td><td>0.202</td></tr><tr><td>&#x02003;Allele T vs. C</td><td>1.2 (1.0 to 1.6)</td><td>0.070</td><td>1.3 (1.0 to 1.8)</td><td>0.037</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for diabetes, hypertension, cigarette smoking, opium addiction, BMI, and family history of CAD as well as triglyceride, HDL-C, and LDL-C</p><p>CAD, coronary artery disease; BMI, body mass index; CI, confidence interval; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Ref., the reference category</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref> shows the association between the studied polymorphism and the severity of CAD with respect to vessel score and Gensini score. The distribution of vessel score was statistically similar among different genotypes (adjusted <italic>p</italic>&#x02009;=&#x02009;0.309). Additionally, in total population, the median and inter-quartile range for Gensini score was not significantly different among the CC (42, 20 to 65), CT (42, 23 to 75), and TT (37, 20 to 64) genotypes (adjusted <italic>P</italic>&#x02009;=&#x02009;0.540). There was also no significant association between the examined polymorphism and the severity of CAD within men or women subgroups.<table-wrap id="Tab6"><label>Table 6</label><caption><p>The genotypes of rs5888 single nucleotide polymorphism in association with CAD severity</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>CC (<italic>n</italic>&#x02009;=&#x02009;357)</th><th>CT (<italic>n</italic>&#x02009;=&#x02009;540)</th><th>TT (<italic>n</italic>&#x02009;=&#x02009;154)</th><th>
<italic>P</italic>-value</th><th>
<italic>P</italic>-value<sup>*</sup>
</th></tr></thead><tbody><tr><td>Vessel score, n (%)</td><td/><td/><td/><td>0.178</td><td>0.247</td></tr><tr><td>&#x02003;0</td><td>195 (54.6)</td><td>281 (52.0)</td><td>70 (45.3)</td><td/><td/></tr><tr><td>&#x02003;1VD</td><td>72 (20.2)</td><td>117 (21.7)</td><td>46 (29.9)</td><td/><td/></tr><tr><td>&#x02003;2VD</td><td>40 (11.2)</td><td>74 (13.7)</td><td>22 (14.3)</td><td/><td/></tr><tr><td>&#x02003;3VD</td><td>50 (14.0)</td><td>68 (12.6)</td><td>16 (10.4)</td><td/><td/></tr><tr><td colspan="6">Gensini score, median (25th to 75th percentiles), n<sup>a</sup>.</td></tr><tr><td>&#x02003;All</td><td>42 (20 to 65), 162</td><td>42 (23 to 75), 259</td><td>37 (20 to 64), 84</td><td>0.449</td><td>0.572</td></tr><tr><td>&#x02003;Males</td><td>43 (26 to 77), 81</td><td>40 (23 to 67), 115</td><td>36 (25 to 61), 38</td><td>0.816</td><td>0.697</td></tr><tr><td>&#x02003;Females</td><td>40 (20 to 64), 81</td><td>45 (23 to 78), 144</td><td>38 (18 to 66), 46</td><td>0.233</td><td>0.398</td></tr></tbody></table><table-wrap-foot><p>
<italic>0</italic> no coronary lesion, <italic>1VD</italic> one-vessel disease, <italic>2VD</italic> Two-vessel disease, <italic>3VD</italic> three-vessel disease, <italic>CAD</italic> coronary artery disease, <italic>HDL-C</italic> high density lipoprotein cholesterol, <italic>LDL-C</italic> low density lipoprotein cholesterol</p><p>
<sup>*</sup>
<italic>P</italic>-values adjusted for diabetes mellitus, cigarette smoking, opium addiction, hypertension, and family history of CAD as well as body mass index, serum HDL-C, triglyceride, and LDL-C</p><p>
<sup>a</sup>A total number of 505 patients after excluding 546 with normal coronary arteries (Gensini score&#x02009;=&#x02009;0)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>The importance of SCARB1 in reverse cholesterol transport and atherosclerosis has been previously confirmed in mouse models [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, recent studies have demonstrated rs5888 variant within SCARB1 to be linked with lipid levels and the size of lipoprotein particles, especially in younger women [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, the role of this variant in CAD development among humans is much less investigated [<xref ref-type="bibr" rid="CR25">25</xref>]. Here we report, for the first time to our knowledge, that the SNP rs5888 in the SCARB1 gene is possibly an independent risk factor for early onset CAD in a cohort of young Iranian patients undergoing elective coronary angiography. In this study we focused on young patients with CAD because we wanted to investigate a cohort of patients who less affected by the age-related confounding factors; this strategy is more likely to detect genetic effects. The logistic regression model demonstrated that T allele in comparison with C allele had 1.3-fold increased risk for PCAD in whole and in women subgroup. Also, in men, the T allele showed a 20&#x000a0;% higher risk for CAD compared to C allele but this did not reach a statistical significance.</p><p>Among our study population, rs5888 within SCARB1 gene is a common SNP with minor allele frequency around 40&#x000a0;%. The variant allele of SNP rs5888 (T allele) frequency was 0.403 in total; 0.423 in case group and 0.386 in reference group. In a cross-sectional health survey on Lithuanian population, T allele frequency in the reference and MI groups was 0.362 and 0.400, respectively [<xref ref-type="bibr" rid="CR18">18</xref>], whereas in Korean subjects the T allelic frequency was 0.330 in control and 0.170 in CAD [<xref ref-type="bibr" rid="CR16">16</xref>]. In white population, the prevalence of this variant varies between 0.400 and 0.600 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Among the participant of the Framingham Offspring Study, wherein almost all were Caucasian, the frequency of T allele was 0.486 [<xref ref-type="bibr" rid="CR28">28</xref>], while in Chinese population T allele frequency varies from 0.217 to 0.290 [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. These studies suggest that the frequency of rs5888 mutation is different in various surveys with various sample sizes, in various geographical regions, and in various ethnic populations. Our finding that T allele may be a significant, independent risk factor for CAD is consistent with the results of a recent candidate gene association study on Chinese [<xref ref-type="bibr" rid="CR14">14</xref>], but this is in contrast to the other similar studies [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. In a Tunisian population, Rejab et al. [<xref ref-type="bibr" rid="CR17">17</xref>] reported that subjects carrying T allele were associated with an almost 41&#x000a0;% reduced risk of angiographically documented significant coronary stenosis. Several other studies on Korean, Spanish, and Lithuanian patients also suggested that the T allele was associated with lower CAD risk [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Such disparity in study results may be ascribed to methodological heterogeneity (differences in study designs, sample sizes, definition of the phenotype, and, age and gender), different genetic background, and differences in the nature of various populations. For example, the precise definition of phenotype in studies on CAD association is of essential importance because individuals with significant CAD who are clinically silent may be classified as controls leading to a higher likelihood of null results. To avoid this potential bias in the current study, we defined phenotype based on objective angiographic documentation of coronary artery status. Notably, the examined polymorphism (rs5888) is not among the list of 46 loci that previously described to be robustly associated with CAD in large-scale genome-wide association studies (GWAS) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In the largest GWAS meta-analysis of CAD undertaken to date, the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) consortium (CARDIoGRAMplusC4D), involving European and South Asian descent, 15 new susceptibility loci were identified [<xref ref-type="bibr" rid="CR31">31</xref>]. Four of the 30 CAD risk loci previously reported in individuals of European ancestry (CDKN2B-AS1, COL4A2, CXCL12 and APOE) were detected as independent additional SNPs not in LD (r<sup>2</sup>&#x02009;&#x0003c;&#x02009;0.5) with the lead SNP, which also reached genome-wide significance. The additional SNP in the APOE locus was rs445925 (<italic>P</italic>&#x02009;=&#x02009;9.42&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;11</sup>; r<sup>2</sup>&#x02009;=&#x02009;0.015 with rs207560 in 1000 Genomes Project data) [<xref ref-type="bibr" rid="CR31">31</xref>]. There was no trend for higher odds ratios (ORs) in any of the subgroup analyses; however, one new locus reached genome-wide significance in males and in young CAD cases (rs16986953; <italic>P</italic>&#x02009;=&#x02009;1.89&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup> and 1.67&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup>, respectively), which was located in a gene desert (with nearest transcript AK097927), 1.3&#x000a0;Mb away from the APOB gene [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Even though several studies having suggested association between the genotypes of rs5888 gene polymorphism and various clinical parameters, the causative role of this variant is still unknown. Indeed, the exon 8 variant (rs5888) is a common synonymous or silent SNP that does not encode for a change in amino acid sequence of the protein product. Although this silent polymorphism was conventionally believed to be a nonfunctional marker in linkage disequilibrium with an as-yet-unidentified causal variant [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], no linkage has been found between this SNP and a known functional promoter variant [<xref ref-type="bibr" rid="CR15">15</xref>]. Also, the promoter variant appears to be extremely rare (0.020) in white populations [<xref ref-type="bibr" rid="CR15">15</xref>]. On the other hand, recent accumulating evidence indicates that silent SNPs could directly influence expression and/or function of their gene products [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]; using in vitro models, Constantineau et al. [<xref ref-type="bibr" rid="CR12">12</xref>] demonstrated that synonymous rs5888 variant affected the RNA secondary structure and conformation of its gene product, SR-BI, and was significantly associated with lower SR-BI expression and its functionality. Hence, SCARB1 rs5888 T allele may possibly alter SR-BI expression, and in turn, influence risk for development of CAD. Moreover, another possible mechanism for this association may be related to some splicing regulatory role [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>We found no associations between SCARB1 rs5888 (C&#x02009;&#x0003e;&#x02009;T) genotypes and lipid profile in our studied patients. In two other studies, the investigators also did not find such associations, when combined with other polymorphisms in the SCARB1 gene, the combined genotypes were related to triglyceride and HDL-C in the women [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, the association between SCARB1 gene and lipid profile is complex and still debated [<xref ref-type="bibr" rid="CR18">18</xref>]. Another notable issue is that subgroup analysis of men and women demonstrated significant different frequencies of rs5888 variant of SCARB1 gene exclusively in women. Significant sex-dependent associations between SCARB1 genetic variations with lipid profile, BMI, and risk of cardiovascular disease have been previously shown [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. As noted by Ritsch et al. [<xref ref-type="bibr" rid="CR32">32</xref>], this phenomenon may be justified by a likely interaction between SCARB1 genotype and estrogen-dependent regulation of SR-BI expression and lipid parameters or by a possible effect of sex on factors affecting the function of SR-BI; factors such as cholesteryl gradient within the cells, HDL-C plasma concentration and composition of its particles, and triglyceride levels that influence HDL-C metabolism via cholesterol ester transfer protein.</p><p>There are several limitations in the present study that should be noted. First, because of case-control design, a selection bias may have been introduced. Second, the control group is not representative of the general healthy population, because it is enriched for people with a high clinical suspicion of having significant CAD, and although coronary stenosis is ruled out, cardiovascular risk factors can be assumed to be higher in this group as compared to the general population. Third, although we tested a relatively large number of patients with PCAD, our study was under-powered to detect the 1.2-fold effect size in male subjects with risk allele (T). Fourth, our results from a single-center may not be generalized to other ethnic groups; however, our tertiary referral center receives patients from all over the country with various ethnic backgrounds. Finally, the lack of ethnicity data in the present study is a major limitation that might explain some of the discrepancy with other studies particularly because the population was from various ethnic backgrounds; therefore, caution needs to be exercised in drawing conclusions about the impact of the examined SNP on PCAD.</p></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusion</title><p>Using angiographic data and thus refining the phenotype, we found that the SNP (rs5888) within SCARB1 is independently associated with PCAD in whole study population and in women, but no association was observed in men. However, the statistical power was not sufficient to detect an association in male subgroup. Further studies, particularly in those with PCAD, with larger sample size in sex subgroups are required to confirm such association in well-defined ethnic groups. Moreover, because many genes are involved in the development of CAD due to dyslipidemia, further investigations are needed to test the relationship between polymorphisms associated with lipid metabolism and the risk of CAD. In addition, the exact mechanism and biological basis of possible role of rs5888 variant in pathogenesis of CAD needs to be explained.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MAB participated in study design, have revisited critically the manuscript for important intellectual content, and given final approval of the version to be published. MB supervised the molecular genetic studies, participated in the design of the study, and given final approval of the version to be published. SZ have made substantial contributions to conception and design, and interpretation of data. AJ participated in the design of the study, performed the statistical analysis, and involved in drafting the manuscript. HRG participated in study design and acquisition of data, involved in statistical analysis, and drafted the manuscript. All authors read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>This work was part of the PhD thesis of the first author (HG) at Tehran Heart Center (THC) with the support of Tehran University of Medical Sciences (TUMS).</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celik</surname><given-names>T</given-names></name><name><surname>Iyisoy</surname><given-names>A</given-names></name></person-group><article-title>Premature coronary artery disease in young patients: an uncommon but growing entity</article-title><source>Int J Cardiol</source><year>2010</year><volume>144</volume><issue>1</issue><fpage>131</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2008.12.150</pub-id><pub-id pub-id-type="pmid">19174320</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sutter</surname><given-names>J</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Sans</surname><given-names>S</given-names></name><name><surname>Py&#x000f6;r&#x000e4;l&#x000e4;</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><etal/></person-group><article-title>Screening of family members of patients with premature coronary heart disease Results from the EUROASPIRE II family survey</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>3</issue><fpage>249</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S0195-668X(02)00386-X</pub-id><pub-id pub-id-type="pmid">12590902</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name><name><surname>Ghaneialvar</surname><given-names>H</given-names></name><name><surname>Rahimi</surname><given-names>Z</given-names></name><name><surname>Nomani</surname><given-names>H</given-names></name><name><surname>Saidi</surname><given-names>M</given-names></name><name><surname>Bahrehmand</surname><given-names>F</given-names></name><etal/></person-group><article-title>The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease</article-title><source>Clin Biochem</source><year>2010</year><volume>43</volume><issue>15</issue><fpage>1189</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2010.07.010</pub-id><pub-id pub-id-type="pmid">20655894</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cengel</surname><given-names>A</given-names></name><name><surname>Tanindi</surname><given-names>A</given-names></name></person-group><article-title>Myocardial infarction in the young</article-title><source>J Postgrad Med</source><year>2009</year><volume>55</volume><issue>4</issue><fpage>305</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.4103/0022-3859.58944</pub-id><pub-id pub-id-type="pmid">20083887</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Marz</surname><given-names>W</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Masana</surname><given-names>L</given-names></name><name><surname>Cavanna</surname><given-names>J</given-names></name><etal/></person-group><article-title>Coronary artery disease and dyslipidemia within Europe: genetic variants in lipid transport gene loci in German subjects with premature coronary artery disease</article-title><source>Atheroscler Suppl</source><year>2002</year><volume>3</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S1567-5688(01)00003-4</pub-id><pub-id pub-id-type="pmid">12044583</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Luthra</surname><given-names>K</given-names></name><name><surname>Dwivedi</surname><given-names>M</given-names></name><name><surname>Behl</surname><given-names>VK</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name></person-group><article-title>Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case-controlled study in Asian Indians in North India</article-title><source>Ann Clin Biochem</source><year>2003</year><volume>40</volume><issue>Pt 4</issue><fpage>382</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1258/000456303766477020</pub-id><pub-id pub-id-type="pmid">12880539</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>KA</given-names></name><name><surname>Strunz</surname><given-names>CM</given-names></name><name><surname>Maranhao</surname><given-names>RC</given-names></name><name><surname>Mansur</surname><given-names>AP</given-names></name></person-group><article-title>The S447X polymorphism of lipoprotein lipase: effect on the incidence of premature coronary disease and on plasma lipids</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>88</volume><issue>3</issue><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1590/S0066-782X2007000300008</pub-id><pub-id pub-id-type="pmid">17533471</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Herbison</surname><given-names>CE</given-names></name><name><surname>Mamotte</surname><given-names>CD</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>RR</given-names></name><name><surname>van Bockxmeer</surname><given-names>FM</given-names></name></person-group><article-title>Hepatic lipase gene -514 C/T polymorphism and premature coronary heart disease</article-title><source>J Cardiovasc Risk</source><year>2002</year><volume>9</volume><issue>2</issue><fpage>105</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/00043798-200204000-00006</pub-id><pub-id pub-id-type="pmid">12006918</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Aziz</surname><given-names>TA</given-names></name><name><surname>Mohamed</surname><given-names>RH</given-names></name><name><surname>Hagrass</surname><given-names>HA</given-names></name></person-group><article-title>Increased risk of premature coronary artery disease in Egyptians with ABCA1 (R219K), CETP (TaqIB), and LCAT (4886C/T) genes polymorphism</article-title><source>J Clin Lipidol</source><year>2014</year><volume>8</volume><issue>4</issue><fpage>381</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2014.06.001</pub-id><pub-id pub-id-type="pmid">25110219</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Eck</surname><given-names>M</given-names></name><name><surname>Pennings</surname><given-names>M</given-names></name><name><surname>Hoekstra</surname><given-names>M</given-names></name><name><surname>Out</surname><given-names>R</given-names></name><name><surname>Van Berkel</surname><given-names>TJ</given-names></name></person-group><article-title>Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis</article-title><source>Curr Opin Lipidol</source><year>2005</year><volume>16</volume><issue>3</issue><fpage>307</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1097/01.mol.0000169351.28019.04</pub-id><pub-id pub-id-type="pmid">15891392</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineo</surname><given-names>C</given-names></name><name><surname>Shaul</surname><given-names>PW</given-names></name></person-group><article-title>Functions of scavenger receptor class B, type I in atherosclerosis</article-title><source>Curr Opin Lipidol</source><year>2012</year><volume>23</volume><issue>5</issue><fpage>487</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/MOL.0b013e328357ba61</pub-id><pub-id pub-id-type="pmid">22907331</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantineau</surname><given-names>J</given-names></name><name><surname>Greason</surname><given-names>E</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Filbin</surname><given-names>M</given-names></name><name><surname>Kieft</surname><given-names>JS</given-names></name><name><surname>Carletti</surname><given-names>MZ</given-names></name><etal/></person-group><article-title>A synonymous variant in scavenger receptor, class B, type I gene is associated with lower SR-BI protein expression and function</article-title><source>Atherosclerosis</source><year>2010</year><volume>210</volume><issue>1</issue><fpage>177</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.11.029</pub-id><pub-id pub-id-type="pmid">20060115</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acton</surname><given-names>S</given-names></name><name><surname>Osgood</surname><given-names>D</given-names></name><name><surname>Donoghue</surname><given-names>M</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Pocovi</surname><given-names>M</given-names></name><name><surname>Cenarro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1999</year><volume>19</volume><issue>7</issue><fpage>1734</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.19.7.1734</pub-id><pub-id pub-id-type="pmid">10397692</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DF</given-names></name><name><surname>Yin</surname><given-names>RX</given-names></name><name><surname>Cao</surname><given-names>XL</given-names></name><name><surname>Chen</surname><given-names>WX</given-names></name><name><surname>Aung</surname><given-names>LH</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Scavenger receptor class B type 1 gene rs5888 single nucleotide polymorphism and the risk of coronary artery disease and ischemic stroke: a case-control study</article-title><source>Int J Med Sci</source><year>2013</year><volume>10</volume><issue>12</issue><fpage>1771</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.7150/ijms.7044</pub-id><pub-id pub-id-type="pmid">24151447</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Esparragon</surname><given-names>F</given-names></name><name><surname>Rodriguez-Perez</surname><given-names>JC</given-names></name><name><surname>Hernandez-Trujillo</surname><given-names>Y</given-names></name><name><surname>Macias-Reyes</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>A</given-names></name><name><surname>Caballero</surname><given-names>A</given-names></name><etal/></person-group><article-title>Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><issue>4</issue><fpage>854</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000157581.88838.03</pub-id><pub-id pub-id-type="pmid">15681296</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>YR</given-names></name><name><surname>Yoon</surname><given-names>YM</given-names></name><name><surname>Min</surname><given-names>WK</given-names></name><name><surname>Chun</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>JQ</given-names></name></person-group><article-title>Association between HaeIII polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration</article-title><source>Ann Clin Biochem</source><year>2002</year><volume>39</volume><issue>Pt 5</issue><fpage>478</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1258/000456302320314485</pub-id><pub-id pub-id-type="pmid">12227853</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rejeb</surname><given-names>J</given-names></name><name><surname>Omezzine</surname><given-names>A</given-names></name><name><surname>Boumaiza</surname><given-names>I</given-names></name><name><surname>Rebhi</surname><given-names>L</given-names></name><name><surname>Kacem</surname><given-names>S</given-names></name><name><surname>Rejeb</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Association of three polymorphisms of scavenger receptor class BI gene (exon8, exon1, intron5) with coronary stenosis in a coronary Tunisian population</article-title><source>Gene</source><year>2012</year><volume>511</volume><issue>2</issue><fpage>383</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.09.070</pub-id><pub-id pub-id-type="pmid">23041084</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanislovaitiene</surname><given-names>D</given-names></name><name><surname>Lesauskaite</surname><given-names>V</given-names></name><name><surname>Zaliuniene</surname><given-names>D</given-names></name><name><surname>Smalinskiene</surname><given-names>A</given-names></name><name><surname>Gustiene</surname><given-names>O</given-names></name><name><surname>Zaliaduonyte-Peksiene</surname><given-names>D</given-names></name><etal/></person-group><article-title>SCARB1 single nucleotide polymorphism (rs5888) is associated with serum lipid profile and myocardial infarction in an age- and gender-dependent manner</article-title><source>Lipids Health Dis</source><year>2013</year><volume>12</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-12-24</pub-id><pub-id pub-id-type="pmid">23510561</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gensini</surname><given-names>GG</given-names></name></person-group><article-title>A more meaningful scoring system for determining the severity of coronary heart disease</article-title><source>Am J Cardiol</source><year>1983</year><volume>51</volume><issue>3</issue><fpage>606</fpage><pub-id pub-id-type="doi">10.1016/S0002-9149(83)80105-2</pub-id><pub-id pub-id-type="pmid">6823874</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boroumand</surname><given-names>M</given-names></name><name><surname>Ghaedi</surname><given-names>M</given-names></name><name><surname>Mohammadtaghvaei</surname><given-names>N</given-names></name><name><surname>Pourgholi</surname><given-names>L</given-names></name><name><surname>Anvari</surname><given-names>MS</given-names></name><name><surname>Davoodi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of estrogen receptor alpha gene polymorphism with the presence of coronary artery disease documented by coronary angiography</article-title><source>Clin Biochem</source><year>2009</year><volume>42</volume><issue>9</issue><fpage>835</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2009.01.005</pub-id><pub-id pub-id-type="pmid">19318036</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boroumand</surname><given-names>M</given-names></name><name><surname>Pourgholi</surname><given-names>L</given-names></name><name><surname>Ziaee</surname><given-names>S</given-names></name><name><surname>Anvari</surname><given-names>MS</given-names></name><name><surname>Jalali</surname><given-names>A</given-names></name><name><surname>Goodarzynejad</surname><given-names>H</given-names></name></person-group><article-title>The association between Factor V Leiden with the presence and severity of coronary artery disease</article-title><source>Clin Biochem</source><year>2014</year><volume>47</volume><issue>6</issue><fpage>356</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2013.12.006</pub-id><pub-id pub-id-type="pmid">24360889</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DF</given-names></name><name><surname>Yin</surname><given-names>RX</given-names></name><name><surname>Yan</surname><given-names>TT</given-names></name><name><surname>Aung</surname><given-names>LH</given-names></name><name><surname>Cao</surname><given-names>XL</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><etal/></person-group><article-title>The SCARB1 rs5888 SNP and serum lipid levels in the Guangxi Mulao and Han populations</article-title><source>Int J Med Sci</source><year>2012</year><volume>9</volume><issue>8</issue><fpage>715</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.7150/ijms.4815</pub-id><pub-id pub-id-type="pmid">23091409</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>CG</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Mitchell</surname><given-names>BD</given-names></name><name><surname>Damcott</surname><given-names>CM</given-names></name><name><surname>Shuldiner</surname><given-names>AR</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name></person-group><article-title>Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women</article-title><source>Hum Hered</source><year>2007</year><volume>64</volume><issue>2</issue><fpage>107</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1159/000101962</pub-id><pub-id pub-id-type="pmid">17476110</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>E</given-names></name><name><surname>von Muhlen</surname><given-names>D</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Alcaraz</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name><name><surname>McCarthy</surname><given-names>JJ</given-names></name></person-group><article-title>Modification of the effects of estrogen therapy on HDL cholesterol levels by polymorphisms of the HDL-C receptor, SR-BI: the Rancho Bernardo Study</article-title><source>Atherosclerosis</source><year>2005</year><volume>180</volume><issue>2</issue><fpage>255</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.12.013</pub-id><pub-id pub-id-type="pmid">15910850</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>WJ</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Kraemer</surname><given-names>FB</given-names></name><name><surname>Azhar</surname><given-names>S</given-names></name></person-group><article-title>Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions</article-title><source>Metabolism</source><year>2014</year><volume>63</volume><issue>7</issue><fpage>875</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2014.03.011</pub-id><pub-id pub-id-type="pmid">24854385</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morabia</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>BM</given-names></name><name><surname>Costanza</surname><given-names>MC</given-names></name><name><surname>Cayanis</surname><given-names>E</given-names></name><name><surname>Flaherty</surname><given-names>MS</given-names></name><name><surname>Alvin</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Population-based study of SR-BI genetic variation and lipid profile</article-title><source>Atherosclerosis</source><year>2004</year><volume>175</volume><issue>1</issue><fpage>159</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.03.014</pub-id><pub-id pub-id-type="pmid">15186961</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Lewitzky</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>C</given-names></name><name><surname>Permutt</surname><given-names>A</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Groop</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Polymorphisms of the HDL receptor gene associated with HDL cholesterol levels in diabetic kindred from three populations</article-title><source>Hum Hered</source><year>2003</year><volume>55</volume><issue>4</issue><fpage>163</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1159/000073986</pub-id><pub-id pub-id-type="pmid">14566094</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osgood</surname><given-names>D</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Demissie</surname><given-names>S</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><issue>6</issue><fpage>2869</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-021664</pub-id><pub-id pub-id-type="pmid">12788901</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>DF</given-names></name><name><surname>Yin</surname><given-names>RX</given-names></name><name><surname>Hu</surname><given-names>XJ</given-names></name><name><surname>Aung</surname><given-names>LH</given-names></name><name><surname>Cao</surname><given-names>XL</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Association of rs5888 SNP in the scavenger receptor class B type 1 gene and serum lipid levels</article-title><source>Lipids Health Dis</source><year>2012</year><volume>11</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-11-50</pub-id><pub-id pub-id-type="pmid">22583964</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Hoed</surname><given-names>M</given-names></name><name><surname>Strawbridge</surname><given-names>RJ</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Gustafsson</surname><given-names>S</given-names></name><name><surname>Axelsson</surname><given-names>T</given-names></name><name><surname>Engstrom</surname><given-names>G</given-names></name><etal/></person-group><article-title>GWAS-identified loci for coronary heart disease are associated with intima-media thickness and plaque presence at the carotid artery bulb</article-title><source>Atherosclerosis</source><year>2015</year><volume>239</volume><issue>2</issue><fpage>304</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.01.032</pub-id><pub-id pub-id-type="pmid">25682028</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Kanoni</surname><given-names>S</given-names></name><name><surname>Willenborg</surname><given-names>C</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Assimes</surname><given-names>TL</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Large-scale association analysis identifies new risk loci for coronary artery disease</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/ng.2480</pub-id><pub-id pub-id-type="pmid">23202125</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritsch</surname><given-names>A</given-names></name><name><surname>Sonderegger</surname><given-names>G</given-names></name><name><surname>Sandhofer</surname><given-names>A</given-names></name><name><surname>Stanzl</surname><given-names>U</given-names></name><name><surname>Tancevski</surname><given-names>I</given-names></name><name><surname>Eller</surname><given-names>P</given-names></name><etal/></person-group><article-title>Scavenger receptor class B type I polymorphisms and peripheral arterial disease</article-title><source>Metabolism</source><year>2007</year><volume>56</volume><issue>8</issue><fpage>1135</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2007.04.009</pub-id><pub-id pub-id-type="pmid">17618962</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komar</surname><given-names>AA</given-names></name></person-group><article-title>Genetics. SNPs, silent but not invisible</article-title><source>Science</source><year>2007</year><volume>315</volume><issue>5811</issue><fpage>466</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1126/science.1138239</pub-id><pub-id pub-id-type="pmid">17185559</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>IW</given-names></name><name><surname>Sauna</surname><given-names>ZE</given-names></name><name><surname>Calcagno</surname><given-names>AM</given-names></name><name><surname>Ambudkar</surname><given-names>SV</given-names></name><etal/></person-group><article-title>A &#x0201c;silent&#x0201d; polymorphism in the MDR1 gene changes substrate specificity</article-title><source>Science</source><year>2007</year><volume>315</volume><issue>5811</issue><fpage>525</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1135308</pub-id><pub-id pub-id-type="pmid">17185560</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komar</surname><given-names>AA</given-names></name></person-group><article-title>Silent SNPs: impact on gene function and phenotype</article-title><source>Pharmacogenomics</source><year>2007</year><volume>8</volume><issue>8</issue><fpage>1075</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2217/14622416.8.8.1075</pub-id><pub-id pub-id-type="pmid">17716239</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Chew</surname><given-names>SL</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><article-title>Listening to silence and understanding nonsense: exonic mutations that affect splicing</article-title><source>Nat Rev Genet</source><year>2002</year><volume>3</volume><issue>4</issue><fpage>285</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrg775</pub-id><pub-id pub-id-type="pmid">11967553</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Lehner</surname><given-names>T</given-names></name><name><surname>Reeves</surname><given-names>C</given-names></name><name><surname>Moliterno</surname><given-names>DJ</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Rogers</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><issue>6</issue><fpage>453</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/jmg.40.6.453</pub-id><pub-id pub-id-type="pmid">12807968</pub-id></element-citation></ref></ref-list></back></article>